title: Factor v Leiden homozygous genotype and pregnancy outcomes.
abstract: OBJECTIVE
  To assess the rate of early (first trimester) and late (second and third trimester) fetal loss in women who are factor V Leiden homozygous.
  
  
  METHODS
  Between December 1995 and February 2007, consecutive, unrelated white women who were factor V Leiden homozygous and who had been pregnant at least once were recruited from 10 French hemostasis units. For reasons of comparison, we included women who were factor V Leiden heterozygous and a group of noncarriers. The frequency of early and late fetal loss was assessed retrospectively and compared among the three groups. The effect of concomitant thrombophilic abnormalities was evaluated. The overall pregnancy outcome was reported.
  
  
  RESULTS
  We analyzed 240 thromboprophylaxis-free pregnancies in 95 women who were factor V Leiden homozygous, 425 in 195 women who were factor V Leiden heterozygous, and 182 in 73 women who were noncarriers. The risk of late fetal loss was higher in women who were homozygous (13/95, 13.7%) compared with those who were noncarriers (1/73, 1.4%, odds ratio 11.41, 95% confidence interval 1.46-89.46, P=.002), whereas it was similar in women who were heterozygous and in noncarriers (6/195, 3.1% compared with 1/73, 1.4%, P=.68). The percentage of women with early fetal loss was similar in the three groups (P=.81). The live-birth rate was 80%, 84%, and 85%, respectively, for women who where homozygous, heterozygous, and noncarriers (P=.88).
  
  
  CONCLUSIONS
  The factor V Leiden homozygous genotype increases the risk of late fetal loss. However, the overall likelihood of a positive outcome is high in our series of women who were homozygous.
  
  
  METHODS
  III.
authors.affiliation: From the Laboratoire d'Hématologie, CHRU Saint-Eloi, Montpellier; Pôle d'Hématologie-Transfusion, Centre de Biologie Pathologie, CHRU bd du Pr. Leclerc, Lille; Hémostase Vasculaire - Hématologie Biologique, CHRU Ch. Nicolle, Rouen; Laboratoire d'Hématologie, CHRU Trousseau, Tours; Laboratoire d'hématologie, CHRU, Caen; Laboratoire d'hématologie, CHRU du bocage, Dijon; Laboratoire d'Hématologie et d'Oncologie Biologique, CHRU, Poitiers; Laboratoire d'hématologie, C.H. J. Monod, 29, Le Havre; Hématologie Biologique, CHRU, Grenoble; and Laboratoire d'Hématologie, CHRU bd J Moulin, Marseille, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Biron-Andréani
authors.forename: Anne
authors.initials: A
authors.lastname: Bauters
authors.forename: Véronique
authors.initials: V
authors.lastname: Le Cam-Duchez
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Delahousse
authors.forename: Agnès
authors.initials: A
authors.lastname: Lequerrec
authors.forename: Fabienne
authors.initials: F
authors.lastname: Dutrillaux
authors.forename: Catherine
authors.initials: C
authors.lastname: Boinot
authors.forename: Catherine
authors.initials: C
authors.lastname: Saladin-Thiron
authors.forename: Benoit
authors.initials: B
authors.lastname: Polack
authors.forename: Yves
authors.initials: Y
authors.lastname: Gruel
authors.forename: Pierre-Emmanuel
authors.initials: PE
authors.lastname: Morange
mesh_terms: D000328:Adult; D015331:Cohort Studies; D020964:Embryo Loss / Q000235:genetics*; D005165:Factor V / Q000235:genetics*; D005260:Female; D005313:Fetal Death / Q000235:genetics*; D005602:France; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000235:genetics*; D012189:Retrospective Studies
chemical_list: C095381:factor V Leiden; D005165:Factor V